Santhera Pharmaceuticals Holding AG
SANN
Rank in Stocks
#16511
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company,... Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Share Price
$17.84
Market Cap
$272.97M
Change (1 day)
-6.69%
Change (1 year)
39.04%
Country
CH
Trade Santhera Pharmaceuticals Holding AG (SANN)
Category
Healthcare
Revenue for Santhera Pharmaceuticals Holding AG (SANN)
Revenue in Oct 2026 TTM: 0
According to Santhera Pharmaceuticals Holding AG latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Santhera Pharmaceuticals Holding AG from 2026 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
